reference/9146533

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9146533

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase II\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	580
issn	0887-6924 1476-5551
issueIdentifier	4
pageRange	573-580
publicationName	Leukemia
startingPage	573
bibliographicCitation	Maloisel F, Guerci A, Guyotat D, Ifrah N, Michallet M, Reiffers J, Tertain G, Blanc M, Bauduer F, Brière J, Abgrall JF, Pegourie-Bandelier B, Solary E, Cambier N, Coso D, Vilque JP, Delain M, Harousseau JL, Rousselot P, Belhadj K, Morice P, Attal J, Chabin M, Chastang C, Guilhot J, Guilhot F; France Intergroupe des Leucémies Myéloïdes Chroniques. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia. 2002 Apr;16(4):573–80. doi: 10.1038/sj.leu.2402433. PMID: 11960335.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c28d1e74e068e60e2ea77a58d365e44a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a276176d40abe7953112563eb718df5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0754496b80e12a58fb49c2c4023a4bf9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a9da424fc854c168cb07761d42cb0db2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_003ffc7466fbd23a232d5dba6a98797d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd2521c415acc010b6103326daa54bae http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31f50f5e812fec449145f6efb9bfc9e8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_484e1258a7ee6344fa1aaecba9b7a206 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f67952e305c63f667ad864f36fef8dc9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bfc7f0acf48b923d841914c40be16e5c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b825934a9554f9ea3649142a9dd5ec1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a47fa414058ee4434cd036656704f8da http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5cd0ef38ec3166e9ee811e839fd556e8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c74dd1aaa4645c3f99a75c0279ac10e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d946b5c8ec56b3840c0d7f9d2ec41955 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2baf6fc1c895ba39429c76c18e11258c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_32add7250a095bde612db77236706f5d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a8b26042076c6521cc04c2439f79f74 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5ac17d58365233a6a19665dba83870b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_667d5cc99ebb4a489032ade4b309853c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42aa5e8df8d9ac359520c9595a693064 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2369191e22d6dce78551a25a8d17c48b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c39a3ccb7af9a0d30431894e9acc48b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a41328c65a502c7ff4e163a1f0ad3062 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b0bec718bf5a81310741fd018efbfbd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_46689dba6babb06934fbcb9e5c7a9aa2
date	2002-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1038/sj.leu.2402433 https://pubmed.ncbi.nlm.nih.gov/11960335
isPartOf	https://portal.issn.org/resource/ISSN/0887-6924 https://portal.issn.org/resource/ISSN/1476-5551 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5536
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase
discusses	http://id.nlm.nih.gov/mesh/M0018641 http://id.nlm.nih.gov/mesh/M0169659 http://id.nlm.nih.gov/mesh/M0005575 http://id.nlm.nih.gov/mesh/M0552528 http://id.nlm.nih.gov/mesh/M0001643 http://id.nlm.nih.gov/mesh/M0025711
hasSubjectTerm	http://purl.org/au-research/vocabulary/anzsrc-for/2008/11 http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6918130 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_850d3dd3f0465864f03b25f855d284d1 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9727 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23671562 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3b4db15610dd7e633a8756b837da2caf http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23663412 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6253

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129367670 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128157154

Total number of triples: 64.